Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
1. Needham initiates coverage on Absci Corporation (ABSI) with a Buy rating. 2. ABSI focuses on drug development using AI/ML and synthetic biology. 3. Collaboration with AMD enhances its AI drug discovery capabilities. 4. The company aims for first-in-class therapies with partners after trials. 5. Price target set at $9, indicating potential growth for ABSI.